Emma Walmsley - GSK Plc President - Consumer Healthcare Worldwide
| GLAXF Stock | USD 16.83 0.21 1.23% |
President
Ms. Emma Walmsley is Chief Executive Officer, Executive Director of GlaxoSmithKline PLC. Prior to her appointment as GSKs CEO, Emma was the CEO of GSK Consumer Healthcare, leading its creation as a Joint Venture between GSK and Novartis in March 2015 . Emma joined GSK in 2010 from LOreal, having worked for 17 years in a variety of roles in Paris, London, New York and Shanghai. Emma holds an MA in Classics and Modern Languages from Oxford University. Emma cochairs the Consumer, Retail and Life Sciences Council, a business advisory group for the UK Government, and is an Honorary Fellow of the Royal Society of Chemistry. since 2017.
| Age | 53 |
| Tenure | 7 years |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GSK Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Miguel Montblanch | Grifols SA ADR | 64 | |
| MarieFrance Tschudin | Novartis AG ADR | 53 | |
| Angela Hwang | Pfizer Inc | 58 | |
| Sandra Leung | Bristol Myers Squibb | 60 | |
| Patrick MD | Novartis AG ADR | 54 | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| Menelas Pangalos | AstraZeneca PLC | 56 | |
| Menelas Pangalos | AstraZeneca PLC ADR | 57 | |
| Murdo Gordon | Amgen Inc | 57 | |
| Kathryn Metcalfe | Bristol Myers Squibb | 50 | |
| David Fredrickson | AstraZeneca PLC ADR | N/A | |
| David Bell | Grifols SA ADR | 70 | |
| Shreeram MD | Novartis AG ADR | 61 | |
| Fiona Marshall | Novartis AG ADR | 60 | |
| Elizabeth Mily | Bristol Myers Squibb | 53 | |
| Samit Hirawat | Bristol Myers Squibb | 52 | |
| Frank DAmelio | Pfizer Inc | 66 | |
| Ruud Dobber | AstraZeneca PLC | N/A | |
| Payal Sahni | Pfizer Inc | 46 | |
| Lidia Fonseca | Pfizer Inc | 55 | |
| Dawn Rogers | Pfizer Inc | 54 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GSK plc Leadership Team
Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Redfern, Chief Strategy Officer | ||
| Diana Conrad, Chief Officer | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Sally Jackson, VP Office | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| James Ford, Senior Vice President General Counsel | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Tony Wood, Chief Officer |
GSK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in GSK Pink Sheet
GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.